Please ensure Javascript is enabled for purposes of website accessibility

Why West Pharmaceutical Services Is Rising Today

By Brian Feroldi - Updated Apr 27, 2017 at 4:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street cheers the company's first-quarter earnings report.

What happened

In response to reported upbeat first-quarter earnings, shares of West Pharmaceutical Services (WST 0.95%), a manufacturer of pharmaceutical packaging and delivery systems, rose by 10% as of 3:25 p.m. EDT on Thursday.

So what

Here's a look at the key numbers from the quarter that captured the market's attention:

  • Revenue grew 7.1%, to $387.7 million.
  • Gross profit margin increased 60 basis points, to 34.6%.
  • EPS jumped 52%, to $0.81, when compared to the $0.53 in adjusted earnings per share (EPS) that was recorded in the year-ago period. However, it's worth noting that this figure included a one-time tax benefit of $0.21. 
  • West Pharmaceutical Services spent $27 million on share buybacks during the quarter. 

By contrast, Wall Street was only expecting $380.4 million in revenue and $0.55 in EPS, so the company beat estimates on both fronts.

Businessman counting money.

Image Source: Getty Images.

Turning to guidance, management reaffirmed its full-year revenue projection, which calls for sales to land between $1.585 billion to $1.610 billion. However, the company adjusted its EPS guidance upward to account for the tax benefit. The new EPS guidance range is $2.66 and $2.78, which compares favorably to its prior outlook of $2.45 and $2.57.

Given the better-than-expected quarterly results and increased profit guidance, it's easy to understand why the market cheered.

Now what

West Pharmaceutical Services continues to prove that selling stoppers, seals, syringes, and cartridge components to the pharmaceutical industry can be a highly lucrative business. The dependable growth in drug demand has provided the company with a strong tailwind that has consistently translated into revenue and profit gains. Given those realities, perhaps it isn't all that surprising to see that the company's stock has vastly outperformed the red-hot biotech industry over the past five years as measured by the iShares Nasdaq Biotechnology ETF (IBB -0.30%).

WST Chart

WST data by YCharts.

Looking ahead, the gradual aging of the global population should ensure that the demand for biologic, generic, and pharmaceutical drugs remains strong for years to come. That's a nice backdrop that provides West Pharmaceutical Services shareholders with plenty of reason to hang on.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

West Pharmaceutical Services, Inc. Stock Quote
West Pharmaceutical Services, Inc.
WST
$302.37 (0.95%) $2.85
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$117.63 (-0.30%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.